GlobeNewswire: CareDx, Inc. Contains the last 10 of 372 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T06:45:34ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/05/24/2449070/0/en/CareDx-Receives-CE-Mark-for-AlloSeq-HCT-for-Use-in-Hematopoietic-Cell-Transplantation.html?f=22&fvtc=4&fvtv=21815CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation2022-05-24T10:00:00Z<![CDATA[CareDx Expands Transplant Portfolio in Europe CareDx Expands Transplant Portfolio in Europe]]>https://www.globenewswire.com/news-release/2022/05/18/2445825/0/en/CareDx-Sponsored-ISHLT-Innovation-Challenge-Award-Tackles-Chronic-Lung-Allograft-Dysfunction.html?f=22&fvtc=4&fvtv=21815CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction2022-05-18T11:00:00Z<![CDATA[Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes]]>https://www.globenewswire.com/news-release/2022/05/17/2444754/0/en/In-CareDx-Initiated-IP-Litigation-Against-Natera-Natera-Now-Drops-1-of-2-Patents-Originally-Asserted-Against-CareDx.html?f=22&fvtc=4&fvtv=21815In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents Originally Asserted Against CareDx2022-05-17T11:00:00Z<![CDATA[Natera Recycles Old IP for New Lawsuits Natera Recycles Old IP for New Lawsuits]]>https://www.globenewswire.com/news-release/2022/05/11/2440644/0/en/CareDx-Showcases-Latest-Innovation-in-Transplantation-at-European-EFI-2022-Conference.html?f=22&fvtc=4&fvtv=21815CareDx Showcases Latest Innovation in Transplantation at European EFI 2022 Conference2022-05-11T11:00:00Z<![CDATA[Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant Monitoring Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant Monitoring]]>https://www.globenewswire.com/news-release/2022/05/05/2437284/0/en/CareDx-Reports-First-Quarter-2022-Results.html?f=22&fvtc=4&fvtv=21815CareDx Reports First Quarter 2022 Results2022-05-05T20:01:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today reported financial results for the first quarter ended March 31, 2022.]]>https://www.globenewswire.com/news-release/2022/05/05/2436571/0/en/CareDx-Validates-Clinical-Performance-of-AlloMap-Kidney-to-Comprehensively-Assess-Transplant-Rejection.html?f=22&fvtc=4&fvtv=21815CareDx Validates Clinical Performance of AlloMap Kidney to Comprehensively Assess Transplant Rejection2022-05-05T11:00:00Z<![CDATA[OKRA Multi-Center Prospective Study Confirms AlloMap Kidney Detects ABMR and TCMR Allograft Rejection OKRA Multi-Center Prospective Study Confirms AlloMap Kidney Detects ABMR and TCMR Allograft Rejection]]>https://www.globenewswire.com/news-release/2022/04/28/2431657/0/en/CareDx-Congratulates-Board-Member-Dr-Hannah-Valantine-on-ISHLT-Lifetime-Achievement-Award.html?f=22&fvtc=4&fvtv=21815CareDx Congratulates Board Member Dr. Hannah Valantine on ISHLT Lifetime Achievement Award2022-04-28T14:45:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Board member Hannah Valantine MD, a recognized leader in driving heart transplantation innovations and health equity, has received the 2022 Lifetime Achievement Award from the International Society for Heart and Lung Transplantation (ISHLT).]]>https://www.globenewswire.com/news-release/2022/04/28/2431189/0/en/CareDx-Extends-Artificial-Intelligence-Leadership-to-Heart-Transplantation.html?f=22&fvtc=4&fvtv=21815CareDx Extends Artificial Intelligence Leadership to Heart Transplantation2022-04-28T11:00:00Z<![CDATA[New Addition to CareDx HeartCare Multimodality Portfolio Can Enable More Precise, Personalized Patient Care New Addition to CareDx HeartCare Multimodality Portfolio Can Enable More Precise, Personalized Patient Care]]>https://www.globenewswire.com/news-release/2022/04/27/2430663/0/en/CareDx-to-Report-First-Quarter-2022-Financial-Results.html?f=22&fvtc=4&fvtv=21815CareDx to Report First Quarter 2022 Financial Results2022-04-27T20:01:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.]]>https://www.globenewswire.com/news-release/2022/04/27/2430375/0/en/International-Society-for-Heart-and-Lung-Transplantation-Foundation-Selects-Reg-Seeto-as-Corporate-Chair.html?f=22&fvtc=4&fvtv=21815International Society for Heart and Lung Transplantation Foundation Selects Reg Seeto as Corporate Chair2022-04-27T13:15:00Z<![CDATA[CareDx CEO and President, Reg Seeto, Joins ISHLT Foundation Global Steering Committee Focused on Driving Innovations for Heart and Lung Transplant Patients CareDx CEO and President, Reg Seeto, Joins ISHLT Foundation Global Steering Committee Focused on Driving Innovations for Heart and Lung Transplant Patients]]>